Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
NoDrugs
ONO-4538, ONO-4578, OpdivoTags
MSS/ MMRpComments
Two arm study:
First arm: ONO-4578 (EP4 antagonist) monotherapy
Second arm: ONO-4578 (EP4 antagonist) combination with ONO-4538 (PD1, Nivolumab, Opdivo)
| Location | Location Status |
|---|---|
| Japan | |
|
Aichi Clinical Site 1 Nagoya, Aichi |
Active, not recruiting |
|
Aichi Clinical Site 2 Toyoake, Aichi |
Active, not recruiting |
|
Chiba Clinical Site 1 Kashiwa, Chiba |
Active, not recruiting |
|
Ehime Clinical Site1 Matsuyama, Ehime |
Active, not recruiting |
|
Gunma Clinical Site 1 Ota, Gunma |
Active, not recruiting |
|
Hokkaido Clinical Site 1 Sapporo, Hokkaido |
Active, not recruiting |
|
Iwate Clinical Site 1 Yahaba-cho, Iwate |
Active, not recruiting |
|
Kanagawa Clinical Site 2 Sagamihara, Kanagawa |
Active, not recruiting |
|
Kanagawa Clinical Site 1 Yokohama, Kanagawa |
Active, not recruiting |
|
Osaka Clinical Site 2 Hirakata, Osaka |
Active, not recruiting |
|
Osaka Clinical Site 3 Sakai, Osaka |
Active, not recruiting |
|
Osaka Clinical Site 4 Takatsuki, Osaka |
Active, not recruiting |
|
Saitama Clinical Site 2 Hidaka, Saitama |
Active, not recruiting |
|
Saitama Clinical Site 1 Ina-machi, Saitama |
Active, not recruiting |
|
Shizuoka Clinical Site 1 Nagaizumi-Cho, Shizuoka |
Active, not recruiting |
|
Tokyo Clinical Site 1 Chuo-ku, Tokyo |
Active, not recruiting |
|
Tokyo Clinical Site 4 Itabashi-ku, Tokyo |
Active, not recruiting |
|
Tokyo Clinical Site 2 Koto-ku, Tokyo |
Active, not recruiting |
|
Tokyo Clinical Site 3 Shinjyuku-ku, Tokyo |
Active, not recruiting |
|
Fukuoka Clinical Site 1 Fukuoka |
Active, not recruiting |
|
Fukuoka Clinical Site 2 Fukuoka |
Active, not recruiting |
|
Osaka Clinical Site 1 Osaka |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
* Advanced or metastatic solid tumors (Part A, B)
* Unresectable, advanced or recurrent gastric cancer previously treated with anti-PD-(L)1 antibodies or naive to anti-PD-(L)1 antibodies (Part C)
* Unresectable, advanced or recurrent colorectal cancer(Part D)
* Life expectancy of at least 3 months
* Patients with ECOG performance status 0 or 1
Exclusion Criteria
Exclusion Criteria:
* Patients with severe complication
* Patients with multiple primary cancers
